4//SEC Filing
Siegel Jolie 4
Accession 0001662579-24-000024
CIK 0001662579other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 7:19 PM ET
Size
12.2 KB
Accession
0001662579-24-000024
Insider Transaction Report
Form 4
Siegel Jolie
Chief Legal Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−84,850→ 0 totalExercise: $45.54Exp: 2031-02-10→ Common Stock (84,850 underlying) - Award
Stock Option (Right to Buy)
2024-03-07+84,850→ 84,850 totalExercise: $19.00Exp: 2031-02-10→ Common Stock (84,850 underlying) - Award
Stock Option (Right to Buy)
2024-03-07+90,000→ 90,000 totalExercise: $19.00Exp: 2032-02-13→ Common Stock (90,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-03-07−90,000→ 0 totalExercise: $22.71Exp: 2032-02-13→ Common Stock (90,000 underlying)
Footnotes (3)
- [F1]On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.
- [F3]The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
Documents
Issuer
C4 Therapeutics, Inc.
CIK 0001662579
Entity typeother
Related Parties
1- filerCIK 0001768223
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 7:19 PM ET
- Size
- 12.2 KB